Anew Medical Receives European Patent for Klotho as Treatment for Neurodegenerative Diseases
Anew Medical (WENA) said Wednesday that it received a patent in Europe for the use of its Klotho gene sequence and gene delivery systems for the treatment of diminished cognition, memory loss, dementia, and other neurodegenerative diseases.
The company said the product's key intellectual property asset is covered under its exclusive worldwide license deal with Universitat Autonoma de Barcelona and Institucio Catalana de Recerca i Estudis Avancats in Spain.
Anew Medical it has also patent approval in China and Hong Kong, and that it plans to start product development and further expand its intellectual property portfolios into Asian markets this year.
Price: 1.6200, Change: -0.03, Percent Change: -1.82
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。